MedinCell announces fiscal year consolidated results April 2019 – March 2020

June 4, 2020

Strong consolidated financial position as at March 31, 2020 and strengthened since year-end
• 12.4 M€ in cash and cash equivalents
• 3.6 M€ of risk-free financial assets (0.4 M€ current + 3.3 M€ non-current)
• 10.9 M€ of additional non-dilutive financing (PGE) – Post-closing
• 3.1 M€ of CIR collected in May 2020 – Post closing
• 5.0 M€ to be received from the EIB under conditions

Consolidated financial results:
• Income from ordinary activities: 6.O M€ (+48% compared to the previous year)
• Cash consumption linked to the activity: 12.5 M€ (in line with expectations)

Evolution of the product portfolio in line with expectations
• Progress in clinical development: Phase 3 of mdc-IRM (antipsychotic), led and funded by Teva Pharmaceuticals and mdc-CWM (post-operative pain and inflammation), funded by AIC
• A third product in clinical development: start of Phase 1 of the mdc-TJK (antipsychotic) product led and financed by Teva Pharmaceuticals
• Two new products in regulatory preclinical studies: mdc-ANG (antipsychotic) and mdc-WWM (contraception), the latter benefiting from a new four-year 19 M$ grant from the Bill & Melinda Gates Foundation
• Three programs close to formulation selection that paves the way for preclinical development: mdc-GRT (organ transplantation), mdc-NVA (pain) and mdc-KPT (animal health)

New program launches:
• mdc-STM: formulation of a 3-month active injectable of Ivermectin to neutralize the vector of malaria transmission, the program received a 6.4 M$ grant over three years from Unitaid
• mdc-STG: new internal program in formulation
• Feasibility study of an injectable long-acting HIV prevention treatment (PrEP) funded by the Gates

Significant post-closing events related to the product portfolio:
• Recruitment completed for the mdc-IRM Phase 3 clinical study, interim analysis expected before the end of 2020
• Completion of the mdc-CWM Phase 2 clinical study, Phase 3 is scheduled to begin by the end of 2020
• Launch of a research program for Covid-19 prevention (prophylaxis)

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.